Injecting the Immune System: Long-Acting TLR7/8 Agonist Shows Promise Against Oral Cancer
A small German cohort study reports that injecting a slow-release TLR7/8 agonist into oral tumors before surgery, combined with systemic ...
A small German cohort study reports that injecting a slow-release TLR7/8 agonist into oral tumors before surgery, combined with systemic ...
A case report describes advanced ovarian cancer shrinking dramatically after the PD-1 inhibitor sintilimab was added to chemotherapy, enabling complete ...
A multicentre retrospective cohort study finds that gastric cancer patients with emotional distress show markedly poorer pathological response to neoadjuvant ...
A retrospective study of 195 colorectal cancer patients found that removing twenty or more tumor-draining lymph nodes after neoadjuvant immunotherapy ...
Final Phase 3 IMpower030 results show that perioperative atezolizumab plus chemotherapy extended median event-free survival to 62.8 months versus 34.9 ...
In a groundbreaking advancement poised to redefine the therapeutic landscape for cervical squamous carcinoma, researchers have unveiled compelling results from ...
In recent years, immune checkpoint blockade (ICB) has revolutionized the treatment landscape for various malignancies, marking a new era in ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine